Cognitive issues are core symptoms of schizophrenia. More than 80 percent of people with schizophrenia have cognitive symptoms of some kind. They’re one of the main obstacles to managing ...

Xanomeline/trospium chloride, a novel M1/M4 muscarinic receptor agonist, is linked to significant cognitive improvement in patients with acute schizophrenia and cognitive impairment in pooled data ...

Boehringer Ingelheim's attempt to develop the first drug therapy for impaired cognitive function in schizophrenia, a core feature of the illness, has suffered what looks like a terminal setback.

Schizophrenia is a serious mental disorder that affects around 1% of the world's population. Researchers have identified a deficit in contrast perception in people with schizophrenia. According to a ...

did not meet the endpoints of improving impaired cognition in individuals with schizophrenia. According to the Company, no statistically significant effects on cognition or functioning were ...

CONNEX was the largest program for cognitive impairment in schizophrenia to date. Boehringer believes that the results will aid scientific understanding and inform future research for patients ...

During the study, there was a steady increase in the PARF for CUD associated with schizophrenia, with no accelerations observed after cannabis policy changes. After medical cannabis liberalization, ...

Using a multi-strain probiotic formulation, researchers conducted a double-blind, randomized, placebo-controlled trial aimed at improving psychiatric and cognitive symptoms, intestinal permeability, ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...